Know Labs Joins IPBC Global 2023 to Discuss the Importance of Strategic IP Development in Maximizing Shareholder Value
May 23 2023 - 9:00AM
Business Wire
Pete Conley, Know Labs’ CFO and SVP of IP, will
share his perspective into why a strategically developed IP
portfolio serves as the foundation for long-term value creation
Know Labs (NYSE American: KNW), an emerging developer of
non-invasive medical diagnostic technology, today announced that
Pete Conley, its Chief Financial Officer and Senior Vice President
of Intellectual Property (IP), will speak at the upcoming 2023
Intellectual Property Business Congress (IPBC) Global event in June
– the world’s largest gathering of leaders and decision-makers
operating in the global IP market.
Mr. Conley is participating as a panelist in a discussion
titled, “Make Your CFO an IP Believer,” with other IP leaders from
HP, Uber, and Deloitte. With over 35 years of experience at the
intersection of IP-related corporate finance, investment banking,
and the forecasting of emerging technologies, Conley will speak to
how a CFO should consider IP as a company’s most valuable asset,
including avoiding the cost-center trap and explaining why a
diversified, strategically developed IP portfolio can be the key to
an organization’s success. He will also highlight how Know Labs
became a global IP leader in the non-invasive blood glucose
monitoring category and the biggest challenges currently facing IP
leaders.
“From my decades of experience in the IP space, I have developed
a deep understanding of the correlation between patent leadership
and value creation, and I am eager to delve into this topic with my
colleagues at IPBC,” said Mr. Conley. “At Know Labs, patents and IP
are the bedrock of our strategy for industry leadership. From this
discussion, I’m hopeful my unique perspective can inform other
leaders about how these essential roles can work harmoniously
together and create sustainable competitive advantage and long-term
shareholder value.”
Mr. Conley has spearheaded Know Labs’ IP strategy for the past
three years as the company continues to expand its industry-leading
patent portfolio. As of March 31, 2023, Know Labs has been ranked
by ipCapital Group, a leading patent analytics firm, as the number
one patent holder in non-invasive glucose monitoring with more than
159 patents issued and pending, a 62 percent increase from 2022’s
year-end total of 98 patents issued and pending. This increase
reinforces Know Labs’ goal of positioning itself as the leading
worldwide IP holder in non-invasive blood glucose monitoring, and
leveraging IP as key to its foundational business strategy.
Currently, blood glucose monitoring is the company’s clinical
focus; however, the extensive patent portfolio for its Bio-RFID™
technology platform reflects more expansive applications in areas
across medical diagnostics, clinical research and industrial
analytics.
Mr. Conley’s panel discussion will take place on June 14th from
1 – 2 p.m. PT at IPBC Global 2023 in San Diego, CA. For more
information on his session, visit
events.iam-media.com/event/. To learn more about Know Labs,
visit https://www.knowlabs.co/.
About Know Labs, Inc.
Know Labs, Inc. is a public company whose shares trade on the
NYSE American Exchange under the stock symbol “KNW.” The Company’s
technology uses spectroscopy to direct electromagnetic energy
through a substance or material to capture a unique molecular
signature. The Company refers to its technology as Bio-RFID™. The
Bio-RFID technology can be integrated into a variety of wearable,
mobile or bench-top form factors. This patented and patent-pending
technology makes it possible to effectively identify and monitor
analytes that could only previously be performed by invasive and/or
expensive and time-consuming lab-based tests. The first application
of our Bio-RFID technology will be in a product marketed as a
non-invasive glucose monitor. It will provide the user with
real-time information on blood glucose levels. This product will
require U.S. Food and Drug Administration clearance prior to its
introduction to the market.
Safe Harbor Statement
This release contains statements that constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. These statements appear in a number of places in this
release and include all statements that are not statements of
historical fact regarding the intent, belief or current
expectations of Know Labs, Inc., its directors or its officers with
respect to, among other things: (i) financing plans; (ii) trends
affecting its financial condition or results of operations; (iii)
growth strategy and operating strategy; and (iv) performance of
products. You can identify these statements by the use of the words
“may,” “will,” “could,” “should,” “would,” “plans,” “expects,”
“anticipates,” “continue,” “estimate,” “project,” “intend,”
“likely,” “forecast,” “probable,” “potential,” and similar
expressions and variations thereof are intended to identify
forward-looking statements. Investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, many of which are beyond Know
Labs, Inc.’s ability to control, and actual results may differ
materially from those projected in the forward-looking statements
as a result of various factors. These risks and uncertainties also
include such additional risk factors as are discussed in the
Company’s filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the fiscal year ended
September 30, 2022, Forms 10-Q and 8-K, and in other filings we
make with the Securities and Exchange Commission from time to time.
These documents are available on the SEC Filings section of the
Investor Relations section of our website at www.knowlabs.co. The
Company cautions readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
The Company undertakes no obligation to update any forward-looking
statement to reflect events or circumstances after the date on
which such statement is made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230523005163/en/
For Know Labs Media Inquiries Contact: Matter
Health Laura Bastardi Knowlabs@matternow.com Ph. (603)
494-6667
Know Labs, Inc. Contact: Jordyn Hujar jordyn@knowlabs.co
Ph. (206) 629-6414
Know Labs (AMEX:KNW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Know Labs (AMEX:KNW)
Historical Stock Chart
From Jul 2023 to Jul 2024